Core Insights - Predictive Oncology Inc. plans to launch its ChemoFx® drug response assay in Europe, focusing on gynecological cancers, particularly ovarian cancer, while expanding its availability in the United States [1][3] - The ChemoFx® assay quantifies individual cancer patients' tumor responses to various chemotherapeutic agents, aiding in personalized treatment selection [2][4] - The company has a biobank of approximately 150,000 live cell tumor samples, with nearly half being gynecological cancers, which supports its AI-driven drug discovery platform [4][6] Company Overview - Predictive Oncology utilizes AI and machine learning to enhance biomarker and drug discovery, achieving a 92% accuracy rate in predicting tumor responses to drug compounds [6] - The ChemoFx® assay previously generated over $25 million in annual gross revenues when first introduced to the market, indicating its potential for significant revenue generation [5] - The company is headquartered in Pittsburgh, PA, and operates a CLIA laboratory to support its drug discovery solutions [6]

Core Insights - Renovaro Inc. has entered into a binding Letter of Intent (LOI) to acquire Predictive Oncology in an all-stock transaction, which will enhance its capabilities in cancer diagnostics and therapeutics powered by artificial intelligence [1][2] Short-Term Synergies - The acquisition provides access to a biobank of over 150,000 tumor specimens and 200,000 pathology slides, which will accelerate biomarker discovery and clinical trial optimization [6] - Predictive Oncology's AI/ML platform has a proven accuracy of 92% in predicting tumor-drug responses, which will support oncologists in making informed treatment decisions [2][8] - The combined organization will streamline the development and rollout of new diagnostic tests in Europe, improving speed to market and expanding global reach [6] Long-Term Vision - The integration of Predictive Oncology's drug discovery platform with Renovaro's liquid biopsy approach aims to create a comprehensive solution for cancer diagnostics and personalized therapies [6] - The partnership is expected to advance cancer therapy at every stage of the patient's journey, improving outcomes and reducing costs [6] - The acquisition will enable collaboration across multi-omic platforms for drug discovery, enhancing the overall capabilities of the combined entity [6] Transaction Details - Renovaro will acquire 100% of Predictive Oncology's common shares through the issuance of Preferred stock [7]

- Combination creates immediate scientific synergies by harnessing complementary AI / ML platforms to improve patient outcomes across multiple cancer indications – - Deal terms align shareholders' interest, augment business development opportunities and positioning in the capital markets - PITTSBURGH, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ:POAI), a leader in AI-driven drug discovery, today announced that it has entered into a binding letter of intent with Renovaro, Inc. (NASDAQ: ...

PITTSBURGH, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, Clinical Laboratory Improvement Amendments (CLIA) laboratory and Good Manufacturing Practices (GMP) facility, to accelerate oncology drug discovery and enable drug development, today announced that it will report its financial results for the second quarter ended June 30, ...

H.C. Wainwright & Co. is acting as the exclusive placement agent for the transaction. The transaction is expected to close on or about July 26, 2024, subject to satisfaction of customary closing conditions. The Company intends to use the net proceeds from the transaction, coupled with an additional $3.58 million in net proceeds raised in May 2024 through the Company's at-the-market facility, for working capital and other general corporate purposes. This press release does not constitute an offer to sell or ...

PITTSBURGH, July 26, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery and biologics, today announced that it has entered into a definitive agreement for the exercise of certain existing warrants to purchase an aggregate of 958,117 shares of its common stock having a current exercise price of $14.00 originally issued in February 2021, June 2021 and May 2022, at a reduced exercise price of $1.32 per share. The issuance and/or resale of the shares of common ...

GPCRs are cell surface membrane receptors that are believed to play a key role in tumorigenesis, with prior studies demonstrating involvement in cancer initiation, progression, and metastasis. It is estimated that drugs targeting GPCRs represent more than 30% of the global market for therapeutic drugs, yet the number of characterized GPCR targets represent just a small fraction of the GPCR superfamily, suggesting significant potential to further target GPCRs for future drug discovery and development2,3. "As ...

Predictive Oncology's organ-specific in vitro models are designed to better mimic the physiological environment of human tissue The 3D cell culture market is projected to grow by more than 14% annually, from $1.4 billion in 2022 to nearly $5.3 billion annually by 20321 PITTSBURGH, June 04, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery and biologics, today announced the availability of its unique 3D cell culture model to advance cancer drug discovery a ...

Core Insights - Predictive Oncology Inc. has introduced a unique 3D cell culture model aimed at enhancing cancer drug discovery and future drug development [1][4] - The 3D cell culture market is projected to grow from $1.4 billion in 2022 to nearly $5.3 billion by 2032, reflecting a compound annual growth rate (CAGR) of over 14% [1][5] Company Overview - Predictive Oncology is leveraging AI and machine learning to expedite early drug discovery, with a scientifically validated AI platform, PEDAL, that predicts tumor response to drug compounds with 92% accuracy [6] - The company maintains a biobank of over 150,000 assay-capable heterogeneous human tumor samples, providing extensive AI-based drug discovery solutions [6] Industry Context - Organ-specific 3D cell cultures offer a more accurate representation of human tissue architecture compared to traditional 2D assays, improving predictions of clinical outcomes and optimizing candidate selection for clinical development [2][4] - The application of 3D cell cultures spans various fields, including pharmaceuticals, regenerative medicine, cancer research, and toxicology, significantly enhancing the accuracy of drug efficacy, toxicity, and pharmacokinetics predictions [5]

PITTSBURGH, May 28, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery and biologics, today announced that positive results from a retrospective study that the company recently completed in collaboration with UPMC Magee-Womens Hospital will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, which is being held May 31-June 4, 2024, in Chicago, Il. The purpose of the study was to determine if Predictive Oncology could lever ...